BioAlliance Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad®
News Aug 27, 2009
BioAlliance Pharma SA has announced positive preliminary results in its LIP phase III pivotal study (Lauriad® Immunocompetent Patients Study).
This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg Mucoadhesive Buccal Tablet (MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes.
In the acyclovir Lauriad® patient group among the 722 patients included, the duration of episode from the first prodromal symptoms to healing was significantly decreased (p= 0.0062).
In addition, the percentage of patients with abortive lesions was increased (p=0.051) and among patients presenting primary vesicular lesions, the time to healing was reduced (p=0.058).
“These data show that acyclovir Lauriad® brings a strong clinical benefit to patients both in preventing and treating recurrent oro-facial herpes. This trial provides a good basis for a constructive dialog with the regulatory authorities. These results strongly validate the Mucoadhesive Buccal Tablet concept based on early targeted treatment”, said Dominique Costantini, President and CEO of BioAlliance Pharma.
Postpartum hemorrhaging is the world's leading cause of death for women during and after childbirth, and the third-leading cause in the United States alone. The drug 'misoprostol' although affordable, has dangerous side effects, including uterine cramping, heart attack, toxicity in the brain and spinal cord, fetal death and fetal heart abnormalities. Development of a safer drug may be on the horizon, based on new researchREAD MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019